Carbon Ion Radiotherapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

— PROMETHEUS-01  

Official title:

Phase I Study Evaluating the Treatment of Patients With Hepatocellular Carcinoma (HCC) With Carbon Ion Radiotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01167374
• Other study ID #: PROMETHEUS-01
• Status: Terminated
• Phase: N/A
• Start date: August 2011
• Est. completion date: August 2022

Study information

• Verified date: November 2022
• Source: University Hospital Heidelberg
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Treatment options for patients with advanced hepatocellular carcinoma (HCC) are often limited. In most cases, they are not amenable to local therapies including surgery or radiofrequency ablation. The multi-kinase inhibitor sorafenib has shown to increase overall survival in this patient group for about 3 months.

Radiation therapy is a treatment alternative, however, high local doses are required for long-term local control. However, due to the relatively low radiation tolerance of liver normal tissue, even using stereotactic techniques, delivery of sufficient doses for successful local tumor control has not be achieved to date.

Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 2 and 3 depending on the HCC cell line as well as the endpoint analyzed.

Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for patients with HCC.

In the current Phase I-PROMETHEUS-01-Study, carbon ion radiotherapy will be evaluated for patients with advanced HCC. The study will be performed as a dose-escalation study evaluating the optimal carbon ion dose with respect to toxicity and tumor control.

Primary endpoint is toxicity, secondary endpoint is progression-free survival and response.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 21
• Est. completion date: August 2022
• Est. primary completion date: August 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• histologically confirmed HCC or diagnosis of HCC according to AASLD-guidelines

• macroscopic tumor

• liver-confined disease without extrahepatic disease as diagnosed by CT, MRT, ultrasound and bone scan

• minimal distance of tumor edge to the intestines of 1cm

• age = 18 years of age

• Karnofsky Performance Score ³60

• For women with childbearing potential, (and men) adequate contraception.

• Ability of subject to understand character and individual consequences of the clinical trial

• Written informed consent (must be available before enrolment in the trial)

Exclusion Criteria:

• refusal of the patients to take part in the study

• previous radiotherapy of the hepatobiliary system

• margin of < 1cm between tumor edge and intestines

• Patients who have not yet recovered from acute toxicities of prior therapies

• Known carcinoma < 2 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy

• Pregnant or lactating women

• Participation in another clinical study or observation period of competing trials, respectively

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma

Intervention

Radiation:
• Carbon Ion Radiotherapy
Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E

Locations

Country	Name	City	State
Germany	University Hospital of Heidelberg, Radiation Oncology	Heidelberg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Heidelberg

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD)	Determination the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of carbon ion radiotherapy	3 months
Secondary	Progression-free Survival		Follow-up until progression up to 12 months